NCT/Study#
NCT05828069 /
COG-ANHL2121
Phase 2 Study of Tovorafenib (DAY101) in Relapsed and Refractory Langerhans Cell Histiocytosis
DISEASE GROUP:
Pediatric Oncology
current phase:
Phase II
STUDY STATUS:
Enrolling
Location:
Hackensack, NJ
For More information:
